The European Commission greenlights RYBREVANT®▼ (amivantamab) alongside chemotherapy for adults with advanced EGFR-mutated NSCLC after previous treatments haven't worked.

Aug 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Tonix Pharmaceuticals partners with Bilthoven Biologicals to advance TNX-801 Mpox vaccine development.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.

Ordspono™ (odronextamab) has received approval in the EU for treating relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.

This approval broadens the scope of the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label.

Alnylam announced on June 14, 2022, that its siRNA drug Amvuttra® (vutrisiran) was approved by the FDA for the treatment of polyneuropathy with hereditary transthyretin-mediated amyloidosis (hATTR) in adults.

Roche has announced that the European Commission has granted approval for PiaSky® (crovalimab), an innovative recycling monoclonal antibody that targets the complement protein C5.

Aug 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

BioArctic AB revealed the publication of the findings from two phase-1 trials involving exidavnemab(ABBV-0805) in The Journal of Clinical Pharmacology.

This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.